IL-17, IL-23 Psoriasis Pathway Inhibitors

Slideshow

The development pipeline for psoriasis in summary.

References:

Content provided by our partner site, Managed Healthcare Executive. 

Related Videos
Related Content
Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg

Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg

April 17th 2024
Article
Overdrive Podcast Update: Guselkumab for Treating Active Psoriatic Arthritis Part 2

Overdrive Podcast Update: Guselkumab for Treating Active Psoriatic Arthritis Part 2

March 14th 2022
Podcast
IL-17A Inhibition Shown to be Superior for Biologic-Naïve Psoriatic Arthritis Patients

IL-17A Inhibition Shown to be Superior for Biologic-Naïve Psoriatic Arthritis Patients

April 11th 2024
Article
Overdrive Podcast: Efficacy of Guselkumab for Treating Psoriatic Arthritis

Overdrive Podcast: Efficacy of Guselkumab for Treating Psoriatic Arthritis

February 23rd 2022
Podcast
Rheumatology Month in Review: March 2024

Rheumatology Month in Review: March 2024

April 2nd 2024
Article
Tildrakizumab Significantly Improves Skin Symptoms in Moderate-to-Severe Psoriasis

Tildrakizumab Significantly Improves Skin Symptoms in Moderate-to-Severe Psoriasis

March 28th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.